209 related articles for article (PubMed ID: 36108149)
21. A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia.
Goral A; Firczuk M; Fidyt K; Sledz M; Simoncello F; Siudakowska K; Pagano G; Moussay E; Paggetti J; Nowakowska P; Gobessi S; Barankiewicz J; Salomon-Perzynski A; Benvenuti F; Efremov DG; Juszczynski P; Lech-Maranda E; Muchowicz A
Front Immunol; 2022; 13():781364. PubMed ID: 35296093
[TBL] [Abstract][Full Text] [Related]
22. B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion.
Asslaber D; Qi Y; Maeding N; Steiner M; Denk U; Höpner JP; Hartmann TN; Zaborsky N; Greil R; Egle A
Blood; 2019 Nov; 134(20):1717-1729. PubMed ID: 31537531
[TBL] [Abstract][Full Text] [Related]
23. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.
Manna A; Kellett T; Aulakh S; Lewis-Tuffin LJ; Dutta N; Knutson K; Chini E; Pinilla-Ibarz J; Lamanna N; Manochakian R; Malavasi F; Sher T; Chanan-Khan AA; Ailawadhi S; Paulus A
Blood Adv; 2020 May; 4(10):2143-2157. PubMed ID: 32421811
[TBL] [Abstract][Full Text] [Related]
24. CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints.
Böttcher M; Böttcher-Loschinski R; Kahlfuss S; Aigner M; Gießl A; Mackensen A; Schlötzer-Schrehardt U; Tüting T; Bruns H; Mougiakakos D
Cells; 2022 Jul; 11(14):. PubMed ID: 35883619
[No Abstract] [Full Text] [Related]
25. EOMES is essential for antitumor activity of CD8
Llaó-Cid L; Roessner PM; Chapaprieta V; Öztürk S; Roider T; Bordas M; Izcue A; Colomer D; Dietrich S; Stilgenbauer S; Hanna B; Martín-Subero JI; Seiffert M
Leukemia; 2021 Nov; 35(11):3152-3162. PubMed ID: 33731848
[TBL] [Abstract][Full Text] [Related]
26. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Immunoregulatory Biomarkers on Plasma Small Extracellular Vesicles for Disease Progression and Early Therapeutic Response in Head and Neck Cancer.
Jablonska J; Rist M; Spyra I; Tengler L; Domnich M; Kansy B; Giebel B; Thakur BK; Rotter N; Lang S; Ludwig S
Cells; 2022 Mar; 11(5):. PubMed ID: 35269524
[TBL] [Abstract][Full Text] [Related]
28. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
[TBL] [Abstract][Full Text] [Related]
29. 2,2'4,4'-Tetrabromodiphenyl Ether (PBDE-47) Modulates the Intracellular miRNA Profile, sEV Biogenesis and Their miRNA Cargo Exacerbating the LPS-Induced Pro-Inflammatory Response in THP-1 Macrophages.
Longo V; Longo A; Adamo G; Fiannaca A; Picciotto S; La Paglia L; Romancino D; La Rosa M; Urso A; Cibella F; Bongiovanni A; Colombo P
Front Immunol; 2021; 12():664534. PubMed ID: 34025666
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-10 receptor signaling promotes the maintenance of a PD-1
Hanna BS; Llaó-Cid L; Iskar M; Roessner PM; Klett LC; Wong JKL; Paul Y; Ioannou N; Öztürk S; Mack N; Kalter V; Colomer D; Campo E; Bloehdorn J; Stilgenbauer S; Dietrich S; Schmidt M; Gabriel R; Rippe K; Feuerer M; Ramsay AG; Lichter P; Zapatka M; Seiffert M
Immunity; 2021 Dec; 54(12):2825-2841.e10. PubMed ID: 34879221
[TBL] [Abstract][Full Text] [Related]
32. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
33. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
[TBL] [Abstract][Full Text] [Related]
34. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
[TBL] [Abstract][Full Text] [Related]
35. ANGPTL2-containing small extracellular vesicles from vascular endothelial cells accelerate leukemia progression.
Huang D; Sun G; Hao X; He X; Zheng Z; Chen C; Yu Z; Xie L; Ma S; Liu L; Zhou BO; Cheng H; Zheng J; Cheng T
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33108353
[TBL] [Abstract][Full Text] [Related]
36. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
[TBL] [Abstract][Full Text] [Related]
37. The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
Matas-Céspedes A; Vidal-Crespo A; Rodriguez V; Villamor N; Delgado J; Giné E; Roca-Ho H; Menéndez P; Campo E; López-Guillermo A; Colomer D; Roué G; Wiestner A; Parren PW; Doshi P; van Bueren JL; Pérez-Galán P
Clin Cancer Res; 2017 Mar; 23(6):1493-1505. PubMed ID: 27637890
[No Abstract] [Full Text] [Related]
38. Chronic lymphocytic leukemia presence impairs antigen-specific CD8
Martens AWJ; Kavazović I; Krapić M; Pack SM; Arens R; Jongejan A; Moerland PD; Eldering E; van der Windt GJW; Wensveen FM; Peters FS; Kater AP
Leukemia; 2023 Mar; 37(3):606-616. PubMed ID: 36658390
[TBL] [Abstract][Full Text] [Related]
39. Antitumor immunity by small extracellular vesicles collected from activated dendritic cells through effective induction of cellular and humoral immune responses.
Matsumoto A; Asuka M; Takahashi Y; Takakura Y
Biomaterials; 2020 Sep; 252():120112. PubMed ID: 32422494
[TBL] [Abstract][Full Text] [Related]
40. BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion.
Liu L; Cheng X; Yang H; Lian S; Jiang Y; Liang J; Chen X; Mo S; Shi Y; Zhao S; Li J; Jiang R; Yang DH; Wu Y
Mol Cancer; 2022 Feb; 21(1):59. PubMed ID: 35193595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
